AP Biosciences (6945.TWO) Stock Price

AP Biosciences Price

CLOSED
117.50
​
Market closed

Revenue at AP Biosciences has contracted by 38.3% per year over the past 3 years to 32.25 M TWD. AP Biosciences's net margin stands at -1,052.0%, down from 0.0% several years earlier.

AP Biosciences stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences business model & stock analysis

AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates.

Frequently asked questions about AP Biosciences

Converted at the current exchange rate, the AP Biosciences share trades at 3.24 EUR (117.50 TWD).

The revenue cannot currently be calculated for AP Biosciences.

The profit cannot currently be calculated for AP Biosciences.

The P/E ratio cannot be calculated for AP Biosciences at the moment.

The P/S cannot be calculated for AP Biosciences currently.

The Eulerpool Quality Score for AP Biosciences is 3/10.

The ISIN of AP Biosciences is TW0006945009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of AP Biosciences is 6945.TWO. The ticker symbol is used to trade AP Biosciences shares on the stock exchange.

Fair ValueTerminal
106.93 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website apbioinc.com
Country
Taiwan
Currency
TWD
Initial public offering
Jul 14, 2023
ISIN
TW0006945009
Cusip
Y0161J106
Market capitalization
10.00 B TWDLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
7.87
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-34.99 %
Last updated Nov 17, 2026, 3:44 AM

AP Biosciences Peer Group

AP Biosciences FIGI

6945:TT (Taipei Stock Exchange) · BBG01HBLJBP0